Merus (MRUS) Expected to Announce Earnings on Wednesday

Merus (NASDAQ:MRUS) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.

Merus (NASDAQ:MRUS) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $9.14 million during the quarter, compared to analysts’ expectations of $10.57 million. On average, analysts expect Merus to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Merus Price Performance

Shares of Merus stock opened at $39.44 on Wednesday. The company has a market cap of $2.73 billion, a PE ratio of -9.98 and a beta of 0.94. The firm has a fifty day moving average price of $43.92 and a two-hundred day moving average price of $44.36. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $61.61.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on MRUS shares. Bank of America decreased their target price on Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. HC Wainwright reissued a “buy” rating and set a $85.00 price objective on shares of Merus in a report on Monday, March 3rd. Guggenheim restated a “buy” rating and set a $109.00 price objective on shares of Merus in a research report on Friday, March 28th. William Blair reaffirmed an “outperform” rating on shares of Merus in a research report on Monday, April 28th. Finally, Wells Fargo & Company began coverage on shares of Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price target on the stock. One analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $85.31.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.